AVTX
Avalo Therapeutics Inc
NASDAQ: AVTX · HEALTHCARE · BIOTECHNOLOGY
$13.20
+2.64% today
Updated 2026-04-29
Market cap
$317.21M
P/E ratio
—
P/S ratio
5,376.53x
EPS (TTM)
$-5.84
Dividend yield
—
52W range
$3 – $21
Volume
0.8M
Avalo Therapeutics Inc (AVTX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82760.00 | — | — | — | $1.15M | $27.81M | $18.33M | $6.75M | $6.70M | $5.40M | $18.05M | $1.92M | $441000.00 | $59000.00 |
| Revenue growth (YoY) | — | -100.0% | — | — | — | +2312.2% | -34.1% | -63.2% | -0.8% | -19.4% | +234.4% | -89.3% | -77.1% | -86.6% |
| Cost of revenue | $8.48M | — | $9.50M | $23508.00 | $8.24M | $635648.00 | $7.48M | $-566523.00 | $300000.00 | $1.49M | $3.43M | $1.28M | $-366000.00 | $344000.00 |
| Gross profit | $-8.39M | — | $-9.50M | $-23508.00 | $-7.09M | $27.18M | $10.85M | $7.32M | $6.40M | $3.91M | $14.62M | $640000.00 | $807000.00 | $-285000.00 |
| Gross margin | -10142.4% | — | — | — | -614.6% | 97.7% | 59.2% | 108.4% | 95.5% | 72.4% | 81.0% | 33.3% | 183.0% | -483.1% |
| R&D | $8.48M | $8.91M | $12.24M | $6.59M | $10.15M | $4.37M | $5.79M | $11.76M | $32.19M | $59.84M | $31.31M | $13.78M | $52.08M | $50.08M |
| SG&A | $2.10M | $4.02M | $4.88M | $4.42M | $7.08M | $7.94M | $10.68M | $10.12M | $17.42M | $23.00M | $20.64M | $10.27M | $16.45M | $22.43M |
| Operating income | $-10.49M | $-12.93M | $-17.12M | $-11.01M | $-16.08M | $13.89M | $-39.31M | $-16.14M | $-26.95M | $-82.13M | $-37.44M | $-27.35M | $-68.51M | $-72.92M |
| Operating margin | -12676.4% | — | — | — | -1394.6% | 49.9% | -214.5% | -239.1% | -402.3% | -1521.6% | -207.4% | -1421.6% | -15535.6% | -123601.7% |
| EBITDA | $-10.48M | $-12.91M | $-17.09M | $-10.46M | $-16.05M | $14.35M | $-13.07M | $-13.51M | $-45.45M | $-80.48M | $-37.27M | $-23.29M | $-68.34M | $-72.92M |
| EBITDA margin | -12658.2% | — | — | — | -1392.3% | 51.6% | -71.3% | -200.1% | -678.5% | -1490.9% | -206.5% | -1210.3% | -15497.3% | -123601.7% |
| EBIT | $-10.49M | $-12.93M | $-17.12M | $-10.48M | $-16.08M | $13.92M | $-14.92M | $-17.39M | $-47.29M | $-82.13M | $-37.44M | $-23.44M | $-68.51M | $-73.27M |
| Interest expense | — | $10555.00 | $1.21M | $793205.00 | $464181.00 | $24016.00 | $811621.00 | $2.91M | $39.34M | $2.39M | $4.17M | $3.42M | $3.32M | — |
| Income tax | — | $110560.00 | $-1.06M | $-543508.00 | $364144.00 | $1.97M | $-33910.00 | $280316.00 | $-2.79M | $-196000.00 | $28000.00 | $14000.00 | $114000.00 | — |
| Effective tax rate | 0.0% | -0.9% | 6.2% | 4.9% | -2.3% | 14.2% | 0.1% | -1.8% | 4.2% | 0.2% | -0.1% | -0.0% | -0.3% | 0.0% |
| Net income | $-10.49M | $-13.05M | $-16.06M | $-10.49M | $-16.47M | $11.87M | $-40.05M | $-16.07M | $-63.50M | $-84.38M | $-41.66M | $-31.54M | $-35.13M | $-78.26M |
| Net income growth (YoY) | — | -24.4% | -23.1% | +34.7% | -57.0% | +172.1% | -437.4% | +59.9% | -295.1% | -32.9% | +50.6% | +24.3% | -11.4% | -122.8% |
| Profit margin | -12674.7% | — | — | — | -1428.5% | 42.7% | -218.5% | -238.1% | -947.9% | -1563.1% | -230.8% | -1639.5% | -7965.8% | -132642.4% |